Limited information is available regarding the linkage between hypertension (HTN) and ischemic stroke based on sex.¹ Recently, at the International Stroke Conference 2022, Dr. Tracey E. Madsen, MD, Associate Director, Division of Sex and Gender, Co-Director at RIH and TMH Stroke Centers, from the United States (US), presented the implications of stroke risk factors in both sexes.¹ The incidence of stroke is primarily attributed to HTN, which is among the various modifiable risk factors.¹ The Greater Cincinnati Northern Kentucky Stroke study showed that the incidence of stroke in both male and female rose significantly with age, predominantly in the older age groups (65-84 years and >85 years), when compared with the younger age groups (20-44 years and 45-64 years).¹ Data showed that women had a lower stroke risk when compared with men in the age groups of 45-65 years and 65-84 years.¹

In the 2022 International Stroke Conference, Dr. Steven Warach from the University of Texas, Austin, the United States, presented the study conducted by himself and his team on the effectiveness of tenecteplase (TNK) compared with alteplase (ALT) on symptomatic intracranial hemorrhage (sICH) in the setting of acute stroke.¹

Large vessel occlusion (LVO), invariably being one of the primary causes of acute ischemic stroke, is associated with poor prognosis if left untreated.¹ Endovascular therapy (EVT) is the conventional treatment for LVO, in case the Alberta stroke program early computed tomography score (ASPECTS) is ≥6.¹ However, if the ischemic core infarction is large with an ASPECTS ≤5, the effectiveness of EVT as an LVO treatment is an unconfirmed observation that requires further conclusive investigations.¹ 

It has been established that speed is crucial for the management of acute ischemic stroke (AIS).1 Although traditional guidelines mainly provide treatment advice based on the standard time window, “tissue clock” illustrated by advance imaging has been shown to extend the treatment window for reperfusion therapies.^2-4